While GLP-1 receptor agonists have not yet been extensively studied for preventing T1D, their ability to improve beta-cell survival and modulate the immune response positions them as promising candidates for future clinical trials in at-risk populations, such as individuals with autoantibody positivity or genetic predisposition to T1D. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.